Semaglutide vs Tirzepatide for Weight Loss: How They Compare

Written by Empire Medical Training Editorial Team

Medically reviewed by Betsy Greenleaf, DO Board-Certified OB/GYN & Urogynecologist; Empire Director of Anti-Aging

Updated June 2026 ·11 min read

Semaglutide and tirzepatide are the two most consequential weight-loss medications in modern metabolic medicine, and they are the two patients most often ask for by name. Both are FDA-approved injectable peptides, both produce weight loss that was unthinkable from a drug a decade ago, and both work primarily through the incretin system. The headline difference is simple: semaglutide activates one receptor, tirzepatide activates two. That single fact drives almost everything downstream — the efficacy numbers, the brands, and how a provider decides which to prescribe.

This comparison is written for clinicians who want an accurate, balanced picture rather than a winner-take-all verdict. It deliberately leans on the underlying compound guides rather than repeating them: for the full clinical overview of each molecule, see semaglutide and tirzepatide, and for the broader category context, our overview of GLP-1 medications for weight loss. This page is clinical education, not medical advice, and nothing here is a treatment recommendation or substitute for current FDA labeling.

The quick answer

If you need the comparison in three sentences: Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist. In clinical trials, tirzepatide has generally produced more weight loss, likely because it engages a second incretin pathway. Both are genuinely effective, FDA-approved, and used as adjuncts to diet and physical activity — so the practical question for a provider is rarely “which is the best drug” but “which is the best drug for this patient.”

The mechanism difference: single vs dual incretin

To compare these drugs honestly you have to start with the incretin system. The gut releases hormones in response to food that prime the pancreas for incoming nutrients — the reason an oral glucose load triggers far more insulin than the same glucose given intravenously. The two incretins that matter here are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

Semaglutide is a GLP-1 receptor agonist. It activates a single incretin receptor, which suppresses appetite in the hypothalamus, slows gastric emptying, enhances glucose-dependent insulin secretion, and suppresses glucagon. That one pathway is enough to drive substantial weight loss.

Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor. As Dr. Betsy Greenleaf frames it in Empire's weight-loss course, tirzepatide “activates both the GIP and GLP-1 receptors, which are involved in the regulation of glucose metabolism and appetite.” The working theory is that adding GIP agonism complements GLP-1 — improving insulin sensitivity and energy handling in a way that amplifies the appetite and metabolic effects of GLP-1 alone. The mechanisms still converge on the same clinical outputs (appetite suppression, increased insulin secretion, reduced glucagon, delayed gastric emptying), but the dual hit appears to push them further. Exactly why two receptors outperform one is still being worked out, but the clinical pattern is consistent.

The brands: what each is called

One of the most practical things to keep straight is that the same molecule carries different brand names depending on whether it is approved for diabetes or for weight management. They are not interchangeable in how they are dosed or labeled.

• Semaglutide — Ozempic and Rybelsus (oral) are approved for type 2 diabetes; Wegovy is approved for chronic weight management. Ozempic and Wegovy also carry cardiovascular indications in defined populations.
• Tirzepatide — Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management.

The rule of thumb: the indication follows the brand, not just the molecule. If weight management is the goal, the on-label products are Wegovy (semaglutide) and Zepbound (tirzepatide). Providers should always work from current approved labeling for dosing, titration, and eligibility.

Efficacy evidence: STEP vs SURMOUNT

Both drugs are backed by large, well-controlled trial programs, which is unusual for this field and a major reason the comparison can be made honestly rather than from anecdote.

Semaglutide's evidence comes from the STEP program, which evaluated it for weight management across distinct populations — non-diabetic obesity, type 2 diabetes with obesity, and regimens combining the drug with intensive behavioral therapy. The consistent signal was clinically meaningful weight loss of roughly 15 percent on average in non-diabetic obesity, with patients who have diabetes generally losing somewhat less.

Tirzepatide's evidence comes from the SURMOUNT program. As Dr. Greenleaf summarizes the dose-response in Empire's course, tirzepatide demonstrates roughly 15 percent weight loss at the 5 mg dose, about 19.5 percent at 10 mg, and up to about 20.9 percent at 15 mg — and in trials it has “led to significant weight loss in participants, often exceeding the weight loss seen with GLP-1 receptor agonists alone.”

The honest read: tirzepatide carries a real, clinically meaningful edge on average weight loss, especially at higher doses. But two cautions keep this from being a simple verdict. First, cross-trial comparisons are imperfect — populations and protocols differ — though the head-to-head data also favor tirzepatide. Second, averages hide enormous individual variation: plenty of patients do beautifully on semaglutide, and a meaningful response is typically defined as losing at least 5 percent of body weight by around week 16 on either agent. The point is to set expectations on the distribution, not the headline number.

Semaglutide vs tirzepatide: side-by-side

The table makes the pattern clear: the two are far more alike than different in how they are taken and how they feel, and they separate mainly on the mechanism, the average efficacy, and the current cardiovascular labeling.

Side effects and tolerability

Because both drugs act on the GLP-1 pathway, their side-effect profiles are broadly similar. The most common effects for both are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and for both they are usually most pronounced during dose escalation and tend to ease over time. The shared culprit is slowed gastric emptying, which is also part of why both drugs work.

Both also share the more serious labeled considerations: a boxed warning regarding thyroid C-cell tumors observed in rodents (contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2), plus considerations around pancreatitis and gallbladder events. Neither is used in pregnancy, and both warrant caution in patients with significant gastroparesis.

Whether one is meaningfully better tolerated than the other is not settled — both are generally well tolerated when titrated carefully, and tolerability is highly individual. The clinical lever that matters most is the same for both: escalate slowly, advance only when the current step is tolerated, and step back rather than stop when GI symptoms appear. The specific titration schedules and the syringe math for compounded vials are taught in depth in Empire's medical weight loss course; the principle to take from this page is that careful titration, not the choice of molecule, is what most determines whether a patient stays on therapy.

One shared imperative deserves emphasis on both drugs: a meaningful fraction of the weight lost can be lean muscle mass rather than fat. Every GLP-1 or dual-incretin prescription should travel with a resistance-training recommendation and adequate protein intake, so the weight that comes off comes off in the right proportions.

How providers choose

In practice, the decision is rarely “which drug is strongest in a vacuum.” It is a multi-factor judgment that depends on the patient in front of you:

• Magnitude of weight loss needed. When the goal is the largest possible average reduction, tirzepatide's dose-response data give it the edge.
• Cardiovascular goal. When formal cardiovascular risk reduction is the explicit indication, semaglutide currently carries the established outcomes label.
• Tolerability and history. A patient who has done well or poorly on one agent informs the next choice; both are titrated to tolerance.
• Access and cost. Insurance coverage, formulary status, and out-of-pocket price frequently decide the real-world choice more than the trial percentages.
• Patient selection and contraindications. Both follow BMI-anchored eligibility and the same absolute contraindications, screened before the first prescription.

The clinically honest conclusion is that these are related but distinct tools, not a ranking. A provider who understands incretin biology, the evidence behind each, and how to select and monitor patients can use either one well — and knowing when to reach for which is exactly the judgment that structured training builds. For the broader category picture, our GLP-1 medications for weight loss overview situates both drugs within the full landscape.

Training to prescribe GLP-1 and dual-incretin agents

Prescribing these drugs competently is less about the science being uncertain — it is well established — and more about using them well: patient selection by FDA labeling, structured dose escalation, proactive side-effect management, lean-mass preservation, monitoring, and clear communication about duration and what happens if therapy stops. The compounded-product question adds another layer every prescriber should understand, since compounded semaglutide and tirzepatide sit in a more complicated and shifting regulatory position than the approved branded products.

Empire's curriculum is built around exactly this practical judgment, connecting the science of each molecule to dedicated medical weight loss training for providers who want to build or expand a weight-management practice responsibly.